PERSON
FDA Shakeup: Peter Marks’ Resignation Rattles Biotech Industry
Peter Marks, FDA resignation, biotech stocks, regulatory uncertainty, drug approvals
BioAtla lays off 30% of staff, hunts out partners for ADC and cancer antibody
Staff, Partner in relationship, CAB, BioAtla, 30%
HHS Overhaul: RFK Jr. Cuts 20,000 Jobs in Major Restructuring
Robert F. Kennedy Jr., Department of Health and Human Services (HHS), job cuts, restructuring, Administration for a Healthy America (AHA), chronic disease epidemic, efficiency, cost-saving
FDA to Decide on Merck’s Subcutaneous Keytruda in September 2025
Subcutaneous Keytruda, FDA decision, September 23, 2025, Merck & Co., cancer treatment, PDUFA date
Equillium’s pivotal GvHD study of anti-CD6 antibody comes up short
United States Food and Drug Administration, itolizumab, In complete remission, day, Equillium
Drugmakers fear Trump tariffs will drive up manufacturing costs, hurt medicine access: BIO survey
Manufacture, EU, Surveys, Financial cost, Fear (Mental Process), Bio
Chiesi unveils 430M investment to revitalize Italian production site for inhaler, biologics manufacturing
Investments, Inhaler, Biological Factors, production
Senate confirms Johns Hopkins surgeon Marty Makary to lead FDA amid turbulence at the agency
Makary, Senate, United States Food and Drug Administration, Surgeon, Johns, Agencies, Dr., Marty
Epicrispr raises $68M, will start clinical trial of epigenetic editing for FSHD
Muscular Dystrophy, Facioscapulohumeral, Epicrispr, Clinical Trials, EPI-321
Illumina Reshapes Board: Former FDA Chief Takes Chair, Activist Investor Joins
Illumina, Scott Gottlieb, Keith Meister, board changes, genomics, shareholder value